- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 277 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 226 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 388 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 150 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 239 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| 17.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.01.2025 | 876 | Xetra Newsboard | Das Instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 17.01.2025 The instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 11.11.24 | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 297 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 22,000 | -1,26 % | Intellia (NTLA) Soars 13% to Fresh High | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,716 | +2,47 % | PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| ATAI LIFE SCIENCES | 4,986 | +4,46 % | Analyst Expectations For ATAI Life Sciences' Future | ||
| BIOMERIEUX | 113,10 | -0,70 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,740 | -17,49 % | Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. | KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries... ► Artikel lesen | |
| GENUS | 29,200 | 0,00 % | Genus: Underlying Group Trading In-line With Expectations | LONDON (dpa-AFX) - Genus (GNS.L) issued trading update for fiscal year ended 30 June 2025. The Group said it recorded strong underlying Group trading in-line with expectations. As a result of... ► Artikel lesen | |
| ANAPTYSBIO | 30,200 | +2,72 % | AnaptysBio, Inc.: Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 | SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that... ► Artikel lesen | |
| ABIONYX PHARMA | 4,010 | +6,23 % | ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis | A Global Turning Point for Critical Care Medicine
Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development... ► Artikel lesen | |
| AKESO | 12,400 | 0,00 % | CICC Cuts AKESO's TP to HKD184; Rating Kept Outperform | ||
| XTL BIOPHARMACEUTICALS | 1,020 | +2,51 % | XTL Biopharmaceuticals: CEO Noam Band rückt in den Verwaltungsrat auf | ||
| MEIRAGTX | 7,850 | +3,97 % | MeiraGTx: Raymond James startet Coverage mit "Strong Buy" und Kursziel von 29 US-Dollar | ||
| MAAT PHARMA | 4,280 | -0,70 % | MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,049 | 0,00 % | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 5,980 | +48,39 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,004 (+1.900 %) liegt der Kurs bei 0,004 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.